Market Cap 3.62B
Revenue (ttm) 2.79B
Net Income (ttm) -116.89M
EPS (ttm) N/A
PE Ratio 17.19
Forward PE 15.93
Profit Margin -4.18%
Debt to Equity Ratio -23.41
Volume 2,656,900
Avg Vol 1,723,684
Day's Range N/A - N/A
Shares Out 314.36M
Stochastic %K 77%
Beta 1.21
Analysts Strong Sell
Price Target $13.50

Company Profile

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and r...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 908 947 3120
Fax: 908 947 3146
Address:
400 Crossing Boulevard, 3rd Floor, Bridgewater, United States
PrivateProfiteering
PrivateProfiteering Nov. 22 at 3:47 AM
$AMRX is currently trading at $11.95, showing a strong upward momentum with an RSI of 65.07, indicating it is approaching overbought territory. The 30-day moving average (MA30) at $10.89 and the 50-day moving average (MA50) at $10.54 suggest a bullish trend, as the price is well above these averages. The recent 60-day high of $12.12 indicates resistance, while the low of $9.32 provides a solid support level. Given the current metrics, the directional bias is bullish, but caution is warranted due to the elevated RSI. Suggested entry could be around $11.80 to capitalize on potential upward movement. A stop loss should be placed at $11.50 to limit downside risk. Targets can be set at $12.12 (60D High) and $12.50 for further profit-taking, contingent on price action. Monitor for any signs of reversal as the price approaches resistance levels. https://privateprofiteers.com
0 · Reply
Iightning
Iightning Nov. 21 at 10:48 PM
1ightning® Options Trade Alert (Actionable) | Buy $AMRX Dec 19 $12 Call | Enter: $0.19 Exit: $0.25 | Profit: 33.63% ROI | https://1ightning.com
0 · Reply
PrivateProfiteering
PrivateProfiteering Nov. 21 at 4:14 AM
$AMRX: The stock closed at $11.52, showing strength as it is above the 30-day moving average (MA30) of $10.82 and the 50-day moving average (MA50) of $10.5. The RSI at 64.21 indicates bullish momentum, approaching overbought territory but not yet there, suggesting potential for further upside. The recent high of $12.12 indicates resistance, while the 60-day low of $9.27 provides a clear support level. Directional bias is bullish due to the stock's position relative to its moving averages and the RSI. Suggested entry point is at $11.60, slightly above the last close to confirm upward momentum. Set a stop loss at $11.00 to manage risk. Target 1 is $12.00, just below the 60D high, and Target 2 is $12.10 to capture potential breakout gains. Monitor for any signs of reversal as the stock approaches resistance. https://privateprofiteers.com
0 · Reply
Iightning
Iightning Nov. 21 at 2:05 AM
1ightning® Options Trade Alert (Actionable) | Buy $AMRX Dec 19 $12 Call | Enter: $0.19 Exit: $0.25 | Profit: 33.63% ROI | https://1ightning.com
0 · Reply
PrivateProfiteering
PrivateProfiteering Nov. 20 at 9:30 AM
$AMRX Trade Plan: Market Context: $AMRX closed at $11.64, exhibiting strong momentum with an RSI of 68.53, indicating it is nearing overbought territory but still has room for further gains. The price is above both the 30-day moving average (MA30) of $10.67 and the 50-day moving average (MA50) of $10.37, suggesting a bullish trend. Directional Bias: The current price is approaching the 60-day high of $12.12, which may act as a resistance level. Given the RSI is above 70, caution is warranted as the stock may pull back. Suggested Entry: Consider entering at $11.50, just below the current close, to capitalize on potential upward movement. Stop: Set a stop-loss at $11.00 to limit downside risk. Targets: First target at $12.00, near the psychological level and below the 60D high. Second target at $12.10, just below the 60D high for potential profit-taking. https://privateprofiteers.com
0 · Reply
Iightning
Iightning Nov. 19 at 11:29 PM
1ightning® Options Trade Alert (Actionable) | Buy $AMRX Dec 19 $12 Call | Enter: $0.19 Exit: $0.25 | Profit: 33.63% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 7:45 AM
1ightning® Options Trade Alert (Actionable) | Buy $AMRX Dec 19 $12 Call | Enter: $0.19 Exit: $0.25 | Profit: 33.63% ROI | https://1ightning.com
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Nov. 13 at 9:49 PM
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 13 at 12:10 PM
$AMRX Share Price: $11.90 Contract Selected: Jun 18, 2026 $10 Calls Buy Zone: $2.31 – $2.85 Target Zone: $3.73 – $4.56 Potential Upside: 52% ROI Time to Expiration: 216 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
tamperson
tamperson Nov. 11 at 11:24 PM
$AMRX Congrats to AMRX on the new 12 month high stock price today. Hope the company can increase the price from here.
0 · Reply
Latest News on AMRX
Amneal Receives U.S. FDA Approval for Iohexol Injection

Nov 13, 2025, 4:01 PM EST - 8 days ago

Amneal Receives U.S. FDA Approval for Iohexol Injection


Amneal Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 6:00 AM EDT - 23 days ago

Amneal Reports Third Quarter 2025 Financial Results


Amneal to Report Third Quarter 2025 Results on October 30, 2025

Sep 30, 2025, 4:05 PM EDT - 7 weeks ago

Amneal to Report Third Quarter 2025 Results on October 30, 2025


Amneal Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 6:00 AM EDT - 3 months ago

Amneal Reports Second Quarter 2025 Financial Results


Amneal to Report Second Quarter 2025 Results on August 5, 2025

Jul 9, 2025, 8:00 AM EDT - 4 months ago

Amneal to Report Second Quarter 2025 Results on August 5, 2025


Amneal to Participate at Upcoming Investor Conferences in June

May 29, 2025, 4:05 PM EDT - 6 months ago

Amneal to Participate at Upcoming Investor Conferences in June


US FDA approves Amneal's migraine treatment

May 15, 2025, 8:16 AM EDT - 6 months ago

US FDA approves Amneal's migraine treatment


Amneal Reports First Quarter 2025 Financial Results

May 2, 2025, 6:00 AM EDT - 7 months ago

Amneal Reports First Quarter 2025 Financial Results


Amneal to Report First Quarter 2025 Results on May 2, 2025

Apr 8, 2025, 4:05 PM EDT - 8 months ago

Amneal to Report First Quarter 2025 Results on May 2, 2025


Amneal to Participate at Upcoming Investor Conference

Mar 10, 2025, 4:05 PM EDT - 9 months ago

Amneal to Participate at Upcoming Investor Conference


Amneal to Participate at Upcoming Investor Conferences

Dec 4, 2024, 8:00 AM EST - 1 year ago

Amneal to Participate at Upcoming Investor Conferences


Amneal Reports Third Quarter 2024 Financial Results

Nov 8, 2024, 6:00 AM EST - 1 year ago

Amneal Reports Third Quarter 2024 Financial Results


Melina Kennedy Joins the LDI, Ltd. Board of Managers

Aug 20, 2024, 9:45 AM EDT - 1 year ago

Melina Kennedy Joins the LDI, Ltd. Board of Managers

WBTN


PrivateProfiteering
PrivateProfiteering Nov. 22 at 3:47 AM
$AMRX is currently trading at $11.95, showing a strong upward momentum with an RSI of 65.07, indicating it is approaching overbought territory. The 30-day moving average (MA30) at $10.89 and the 50-day moving average (MA50) at $10.54 suggest a bullish trend, as the price is well above these averages. The recent 60-day high of $12.12 indicates resistance, while the low of $9.32 provides a solid support level. Given the current metrics, the directional bias is bullish, but caution is warranted due to the elevated RSI. Suggested entry could be around $11.80 to capitalize on potential upward movement. A stop loss should be placed at $11.50 to limit downside risk. Targets can be set at $12.12 (60D High) and $12.50 for further profit-taking, contingent on price action. Monitor for any signs of reversal as the price approaches resistance levels. https://privateprofiteers.com
0 · Reply
Iightning
Iightning Nov. 21 at 10:48 PM
1ightning® Options Trade Alert (Actionable) | Buy $AMRX Dec 19 $12 Call | Enter: $0.19 Exit: $0.25 | Profit: 33.63% ROI | https://1ightning.com
0 · Reply
PrivateProfiteering
PrivateProfiteering Nov. 21 at 4:14 AM
$AMRX: The stock closed at $11.52, showing strength as it is above the 30-day moving average (MA30) of $10.82 and the 50-day moving average (MA50) of $10.5. The RSI at 64.21 indicates bullish momentum, approaching overbought territory but not yet there, suggesting potential for further upside. The recent high of $12.12 indicates resistance, while the 60-day low of $9.27 provides a clear support level. Directional bias is bullish due to the stock's position relative to its moving averages and the RSI. Suggested entry point is at $11.60, slightly above the last close to confirm upward momentum. Set a stop loss at $11.00 to manage risk. Target 1 is $12.00, just below the 60D high, and Target 2 is $12.10 to capture potential breakout gains. Monitor for any signs of reversal as the stock approaches resistance. https://privateprofiteers.com
0 · Reply
Iightning
Iightning Nov. 21 at 2:05 AM
1ightning® Options Trade Alert (Actionable) | Buy $AMRX Dec 19 $12 Call | Enter: $0.19 Exit: $0.25 | Profit: 33.63% ROI | https://1ightning.com
0 · Reply
PrivateProfiteering
PrivateProfiteering Nov. 20 at 9:30 AM
$AMRX Trade Plan: Market Context: $AMRX closed at $11.64, exhibiting strong momentum with an RSI of 68.53, indicating it is nearing overbought territory but still has room for further gains. The price is above both the 30-day moving average (MA30) of $10.67 and the 50-day moving average (MA50) of $10.37, suggesting a bullish trend. Directional Bias: The current price is approaching the 60-day high of $12.12, which may act as a resistance level. Given the RSI is above 70, caution is warranted as the stock may pull back. Suggested Entry: Consider entering at $11.50, just below the current close, to capitalize on potential upward movement. Stop: Set a stop-loss at $11.00 to limit downside risk. Targets: First target at $12.00, near the psychological level and below the 60D high. Second target at $12.10, just below the 60D high for potential profit-taking. https://privateprofiteers.com
0 · Reply
Iightning
Iightning Nov. 19 at 11:29 PM
1ightning® Options Trade Alert (Actionable) | Buy $AMRX Dec 19 $12 Call | Enter: $0.19 Exit: $0.25 | Profit: 33.63% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 7:45 AM
1ightning® Options Trade Alert (Actionable) | Buy $AMRX Dec 19 $12 Call | Enter: $0.19 Exit: $0.25 | Profit: 33.63% ROI | https://1ightning.com
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Nov. 13 at 9:49 PM
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 13 at 12:10 PM
$AMRX Share Price: $11.90 Contract Selected: Jun 18, 2026 $10 Calls Buy Zone: $2.31 – $2.85 Target Zone: $3.73 – $4.56 Potential Upside: 52% ROI Time to Expiration: 216 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
tamperson
tamperson Nov. 11 at 11:24 PM
$AMRX Congrats to AMRX on the new 12 month high stock price today. Hope the company can increase the price from here.
0 · Reply
10sense
10sense Nov. 11 at 7:18 PM
0 · Reply
topstockalerts
topstockalerts Nov. 7 at 7:03 PM
S&P Global Ratings revised its outlook on Amneal Pharmaceuticals Inc. to positive from stable while affirming the company’s ‘B+’ credit rating. The agency expects leverage to fall below 4x by 2026, following stronger-than-expected financial results through Q3 2025. Leverage has already improved to 4.2x and is projected to decline to 4.1x in 2025 and 3.7x in 2026. S&P said the improvement is driven by new product launches, including Crexont, a branded Parkinson’s therapy introduced in September 2024, which could reach peak sales of about $500 million by 2030. Amneal has cut leverage sharply from 8.5x in 2019 after founders Chirag and Chintu Patel returned and adopted a more conservative financial policy. Management aims to reduce net leverage below 3x by 2027. $AMRX
0 · Reply
d_risk
d_risk Nov. 7 at 12:16 AM
$AMRX - Amneal Pharmaceuticals Inc. Class A Common Stock - 10Q - Updated Risk Factors AMRX flags a new risk: a U.S. government shutdown could disrupt regulatory approvals, operations, and financial performance. #Pharmaceuticals #FinancialImpact #OperationalRisk #GovernmentShutdown #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/AMRX/10-Q/2025-11-06
0 · Reply
Doozio
Doozio Nov. 6 at 4:36 AM
$AMRX it was always 🐒🍌🧠⏰♾️
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 5 at 3:24 PM
0 · Reply
10sense
10sense Oct. 30 at 5:58 PM
$AMRX great numbers on this one this morning. I have no clue why it's down
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 30 at 12:38 PM
$AMRX (+3.2% pre) Amneal receives tentative FDA approval for generic asthma inhaler https://ooc.bz/l/82505
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 27 at 9:56 PM
Results $AMRX $AMRZ $AMSC $AMT $AMWD 🔥
0 · Reply
resistancebreakers
resistancebreakers Oct. 2 at 7:23 PM
$AMRX insider buys 🔥🪖🫡☝️
1 · Reply
Fishbull
Fishbull Oct. 1 at 11:11 PM
$AMRX Let’s see how far this will go now that 10$ has been crossed
0 · Reply
Mhollenbuy
Mhollenbuy Sep. 30 at 5:32 PM
0 · Reply
Fishbull
Fishbull Sep. 30 at 1:25 AM
$AMRX hoping it crosses 10$
0 · Reply